BG Medicine Aims for Around $67M in IPO

The firm aims to go public at a price of between $13 and $15 per share. It plans to use proceeds to fund the commercial launch of the BGM Galectin-3 test, as well as development of other tests.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories